Labcorp (NYSE:LH) Stock Price Expected to Rise, Truist Financial Analyst Says

Labcorp (NYSE:LH) had its price objective raised by stock analysts at Truist Financial from $320.00 to $350.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Truist Financial’s price target would indicate a potential upside of 12.14% from the stock’s current price.

LH has been the subject of a number of other research reports. Barclays increased their target price on Labcorp from $290.00 to $320.00 and gave the stock an “equal weight” rating in a report on Thursday. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Bank of America increased their price objective on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Robert W. Baird boosted their target price on Labcorp from $335.00 to $338.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, Weiss Ratings raised Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Labcorp currently has an average rating of “Moderate Buy” and an average target price of $322.00.

Labcorp Stock Performance

Shares of LH stock opened at $312.12 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. Labcorp has a 52 week low of $244.52 and a 52 week high of $316.11. The company’s 50 day moving average price is $273.73 and its two-hundred day moving average price is $270.74. The company has a market capitalization of $25.59 billion, a P/E ratio of 27.74, a price-to-earnings-growth ratio of 2.04 and a beta of 0.89.

Labcorp (NYSE:LH) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The company had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.71 billion. During the same quarter in the prior year, the company earned $4.35 earnings per share. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, analysts expect that Labcorp will post 18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Labcorp news, EVP Kathryn W. Kyle sold 92 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $26,329.48. Following the transaction, the executive vice president owned 3,904 shares of the company’s stock, valued at $1,117,285.76. The trade was a 2.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Bryan T. Vaughn sold 234 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total value of $66,968.46. Following the sale, the executive vice president owned 6,746 shares in the company, valued at approximately $1,930,637.74. This represents a 3.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 6,991 shares of company stock worth $1,796,696. Corporate insiders own 0.84% of the company’s stock.

Hedge Funds Weigh In On Labcorp

Institutional investors have recently added to or reduced their stakes in the company. UBS Group AG grew its position in shares of Labcorp by 2.2% in the 4th quarter. UBS Group AG now owns 495,535 shares of the medical research company’s stock valued at $124,320,000 after acquiring an additional 10,706 shares during the period. Fifth Third Bancorp raised its holdings in shares of Labcorp by 106.5% in the 1st quarter. Fifth Third Bancorp now owns 57,981 shares of the medical research company’s stock valued at $15,470,000 after purchasing an additional 29,899 shares during the period. Geode Capital Management LLC raised its holdings in shares of Labcorp by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company’s stock valued at $534,023,000 after purchasing an additional 13,775 shares during the period. CIBC Asset Management Inc lifted its stake in Labcorp by 61.3% in the 4th quarter. CIBC Asset Management Inc now owns 19,974 shares of the medical research company’s stock valued at $5,011,000 after purchasing an additional 7,592 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Labcorp by 103.1% in the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock valued at $1,343,922,000 after purchasing an additional 2,719,475 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reported second-quarter adjusted EPS of $4.99, exceeding the $4.78 analyst consensus, while revenue rose 5.8% year over year to $3.73 billion, slightly above estimates. Reuters earnings article
• Positive Sentiment: Performance was supported by steady diagnostic-testing demand and growth in drug-development services. Diagnostics Laboratory Services revenue increased 5.5% to $2.90 billion, while Biopharma Laboratory Services revenue grew 6.5% to $836.2 million. Management also highlighted opportunities in oncology, consumer health and technology. Labcorp second-quarter results
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $18.10-$18.55, above the roughly $17.99 consensus, and provided revenue guidance of approximately $14.71-$14.83 billion. Labcorp also increased its share-repurchase authorization by $1 billion and repurchased $353.8 million of stock during the quarter. Labcorp Q2 earnings call transcript
• Neutral Sentiment: Management’s earnings-call commentary emphasized margin improvement, organic growth of 4.2% and continued investment in testing capabilities and biopharma services. These trends support the longer-term outlook, although investors will look for evidence that growth can accelerate.
• Negative Sentiment: Shares fell in premarket trading despite the results, suggesting the beat and guidance increase may have been largely anticipated. With LH trading near its 52-week high and at approximately 28 times earnings, investors may have wanted a stronger outlook or more significant upside to justify the valuation. Separate trading data also showed insider selling without reported insider purchases over the past six months, adding a modest sentiment concern. Zacks Labcorp stock reaction article

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.